Ina Bozic

2 papers in the library · 5 citations · publishing 2025-2026

Papers

Sort Most recent Most cited

551. Esketamine in neuropsychiatric long COVID: a retrospective analysis

The International Journal of Neuropsychopharmacology September 1, 2026 N Hartman, D Ivkic, M C Dorczok et al.

Abstract Background Neuropsychiatric manifestations of Long COVID (LC) frequently include post-exertional malaise (Cheng et al., 2025), fatigue, cognitive dysfunction and impairment, sleep disturbances, post-traumatic stress, autonomic dysregulation, pain, inner tension, psychomotor retardation, aberrations in appetite and weight (Badenoch et al., 2022; O'Mahoney et al., 2025), showing...

DOI: 10.1093/ijnp/pyag040.161 Full text

Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy.

Wiener klinische Wochenschrift March 1, 2025 Pia Baldinger-Melich, Marie Spies, Ina Bozic et al. 5 citations

Modern electroconvulsive therapy (ECT) and the approval of nasal esketamine for clinical use have significantly improved the approach to treatment-resistant depression (TRD), which is defined as non-response to at least two different courses of antidepressants with verified adherence to treatment, adequate dosage, and duration of treatment. The goal of this literature review is to present the...

DOI: 10.1007/s00508-024-02358-w Full text Spravato Antidepressant treatment Electroconvulsive therapy ect Treatment-resistant depression trd +6